bullish

Biopharma Week in Review - December 9, 2024

187 Views12 Dec 2024 10:24
Issuer-paid
We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&A. Last week, BIOA discontinued its lead obesity study
What is covered in the Full Insight:
  • Review of Biopharma News
  • BioAge Labs Obesity Study Discontinuation
  • Janux Therapeutics Prostate Cancer Data
  • PTC Therapeutics and Novartis Deal
  • Senti Biosciences AML Trial Results
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 9-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Water Tower Research
Research from Water Tower Research
Water Tower Research
Equity Bottom-UpThematic (Sector/Industry)
  • Loading...
x